Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00770211 · ClinicalTrials.gov registry record · Phase 3
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
A Phase 3 study, sponsored by Merz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 271
- Enrollment target
NCT00770211 is a Phase 3 study that has completed, run by Merz Pharmaceuticals. The registered enrollment target is 271 participants.
The verdict
NCT00770211, a Phase 3 study, has completed, sponsored by Merz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 271 participants
- Enrollment target
Study Summary
The study objective is to show the superior efficacy of IncobotulinumtoxinA (Xeomin) over placebo by evaluation of treatment success analyzing the investigator's rating on the Facial Wrinkle Scale and the patient's assessment on a 4-point scale. 255 female and male patients with moderate to severe glabellar frown lines will be randomized in a 2:1 ratio to receive one injection of IncobotulinumtoxinA (Xeomin) or placebo and will be followed up until day 120.
Interventions
- DRUG Placebo
- DRUG IncobotulinumtoxinA (Xeomin) (20 Units)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 271 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00770211
The ClinicalTrials.gov registry entry for NCT00770211 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 271 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merz Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00770211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00770211 about?
NCT00770211 is a clinical study titled "IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines". The study objective is to show the superior efficacy of IncobotulinumtoxinA (Xeomin) over placebo by evaluation of treatment success analyzing the investigator's rating on the Facial Wrinkle Scale and the patient's assessment on a 4-point scale. 255 female and male patients with moderate to severe g...
What is the current status of trial NCT00770211?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 271 participants. The study started on 2008-10. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00770211?
The interventions under investigation include: Placebo (DRUG), IncobotulinumtoxinA (Xeomin) (20 Units) (DRUG).
Who is sponsoring clinical trial NCT00770211?
This trial is sponsored by Merz Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.